SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:
BTIG Virtual Biotechnology Conference
Date: Monday, August 7th at 2:00pm E.T.
Format: Virtual Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran
Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 8, 2023 in New York, NY
Format: 1x1 Investor Meetings
Canaccord Genuity Annual Growth Conference
Date: Thursday, August 10, 2023 at 1:00pm E.T. in Boston, MA
Format: Fireside Chat and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran
Interested parties can access the live webcasts for these conferences (if available) from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replays will be available after the conclusion of the respective presentations.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani is progressing two RaniPill® capsules, the RaniPill®GO and the RaniPill®HC. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.08 |
| Daily Change: | 0.04 1.96 |
| Daily Volume: | 411,168 |
| Market Cap: | US$60.920M |
November 14, 2024 October 17, 2024 August 06, 2024 June 24, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
